Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer

Sponsor
ShiYue Li
Study ID
NCT04201990
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients. Methods: In this study, 20 patients with MPLC who conform to the admission criteria are enrolled and began to receive treatment with Camrelizumab combined with Apatinib after cryoablation.

Key Dates

Start date
Dec 31, 2019
Status verified
Dec 2019
Primary completion
Dec 31, 2021
Completion
Dec 31, 2022

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    Camrelizumab, iv, Q3W until progression disease or intolerable toxicity or 2 years Apatinib, po, QD until progression disease or intolerable toxicity or 2 years

Primary Outcome Measure

Safety score [ Time Frame: three weeks ]

Central Contacts

Related Studies